Objective:
The objective of this study was to identify factors influencing bioequivalence in generic drug production, focusing on manufacturing consistency, raw material sourcing, and pharmacokinetic performance across facilities located in North America, Europe, and Asia. The study aimed to propose best practices and practical recommendations to address discrepancies in generic drug production and improve adherence to global bioequivalence standards.

Methods:
A comprehensive analysis was conducted across 50 batches of generic drugs obtained from five manufacturing facilities located in North America, Europe, and Asia. The study involved evaluating manufacturing processes, batch consistency, scaling-up techniques, and supplier interactions. Raw materials, including APIs and excipients, were analyzed for purity and compatibility. In-vitro and in-vivo pharmacokinetic assessments were performed using High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) technologies. Statistical analyses, including ANOVA and t-tests, were employed to compare batch consistency, API purity, and pharmacokinetic performance across different regions. Compliance with Good Manufacturing Practice (GMP) guidelines and FDA/EMA regulations was also assessed through supplier audits and documentation reviews.

Results:
The study found significant regional differences in manufacturing consistency and raw material quality. North American and European facilities demonstrated superior batch consistency (98.5% and 96.7%) and API purity (99.2%) due to robust GMP adherence and supplier audits. In contrast, Asian facilities exhibited lower batch consistency (93.2%) and API purity (97.5%). Pharmacokinetic analyses showed that generics from North America and Europe were bioequivalent to brand-name products, while Asian generics exhibited reduced absorption rates (Cmax = 230 ng/mL) and lower AUC values (1100 ng·hr/mL). Statistical tests (ANOVA, t-tests) confirmed significant differences in Cmax and AUC among regions.